Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$18.52 -1.4%	$16.37	$8.02 ▼ $19.08	$9.33B	1.62	10.07 million shs	5.25 million shs
IDXX IDEXX Laboratories	$641.14 -0.6%	$603.59	$356.14 ▼ $688.12	$51.62B	1.56	372,779 shs	317,919 shs
LLY Eli Lilly and Company	$754.90 -0.2%	$741.03	$623.78 ▼ $942.35	$715.79B	0.47	3.74 million shs	2.20 million shs
PAWZ ProShares Pet Care ETF	$56.44 +5.4%	$57.27	$47.58 ▼ $61.12	$76.17M	1.16	5,301 shs	8,836 shs
PETQ PetIQ	$30.98	$30.90	$15.09 ▼ $31.06	$925.99M	1.73	480,624 shs	N/A
PFE Pfizer	$23.91 -3.8%	$24.79	$20.92 ▼ $30.43	$141.34B	0.55	35.00 million shs	81.16 million shs
ZTS Zoetis	$148.33 -1.5%	$152.32	$139.70 ▼ $200.33	$66.75B	0.89	2.28 million shs	3.11 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	-1.45%	+0.66%	+3.85%	+33.99%	+27.88%
IDXX IDEXX Laboratories	-0.62%	-0.29%	-3.43%	+22.66%	+30.78%
LLY Eli Lilly and Company	-0.13%	+3.93%	+14.31%	-7.78%	-18.02%
PAWZ ProShares Pet Care ETF	-0.53%	-2.58%	-2.69%	-2.33%	-3.84%
PETQ PetIQ	0.00%	0.00%	0.00%	0.00%	+1.11%
PFE Pfizer	-3.74%	-3.80%	-4.89%	-2.45%	-19.33%
ZTS Zoetis	-1.55%	-3.15%	-2.66%	-9.70%	-21.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$18.52 -1.4%	$16.37	$8.02 ▼ $19.08	$9.33B	1.62	10.07 million shs	5.25 million shs
IDXX IDEXX Laboratories	$641.14 -0.6%	$603.59	$356.14 ▼ $688.12	$51.62B	1.56	372,779 shs	317,919 shs
LLY Eli Lilly and Company	$754.90 -0.2%	$741.03	$623.78 ▼ $942.35	$715.79B	0.47	3.74 million shs	2.20 million shs
PAWZ ProShares Pet Care ETF	$56.44 +5.4%	$57.27	$47.58 ▼ $61.12	$76.17M	1.16	5,301 shs	8,836 shs
PETQ PetIQ	$30.98	$30.90	$15.09 ▼ $31.06	$925.99M	1.73	480,624 shs	N/A
PFE Pfizer	$23.91 -3.8%	$24.79	$20.92 ▼ $30.43	$141.34B	0.55	35.00 million shs	81.16 million shs
ZTS Zoetis	$148.33 -1.5%	$152.32	$139.70 ▼ $200.33	$66.75B	0.89	2.28 million shs	3.11 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	-1.45%	+0.66%	+3.85%	+33.99%	+27.88%
IDXX IDEXX Laboratories	-0.62%	-0.29%	-3.43%	+22.66%	+30.78%
LLY Eli Lilly and Company	-0.13%	+3.93%	+14.31%	-7.78%	-18.02%
PAWZ ProShares Pet Care ETF	-0.53%	-2.58%	-2.69%	-2.33%	-3.84%
PETQ PetIQ	0.00%	0.00%	0.00%	0.00%	+1.11%
PFE Pfizer	-3.74%	-3.80%	-4.89%	-2.45%	-19.33%
ZTS Zoetis	-1.55%	-3.15%	-2.66%	-9.70%	-21.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELAN Elanco Animal Health	2.78	Moderate Buy	$17.33	-6.39% Downside
IDXX IDEXX Laboratories	2.80	Moderate Buy	$649.44	1.30% Upside
LLY Eli Lilly and Company	2.68	Moderate Buy	$941.35	24.70% Upside
PAWZ ProShares Pet Care ETF	2.61	Moderate Buy	$56.44	N/A
PETQ PetIQ	0.00	N/A	N/A	N/A
PFE Pfizer	2.39	Hold	$28.12	17.60% Upside
ZTS Zoetis	2.56	Moderate Buy	$200.88	35.42% Upside

Current Analyst Ratings Breakdown

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2025	ZTS Zoetis	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$190.00
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/20/2025	ELAN Elanco Animal Health	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	IDXX IDEXX Laboratories	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$722.00 ➝ $765.00
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$942.00 ➝ $875.00
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$210.00 ➝ $215.00

(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELAN Elanco Animal Health	$4.48B	2.05	$2.22 per share	8.33	$12.33 per share	1.50
IDXX IDEXX Laboratories	$3.90B	13.16	$12.35 per share	51.90	$19.48 per share	32.91
LLY Eli Lilly and Company	$45.04B	15.86	$14.21 per share	53.13	$15.03 per share	50.23
PAWZ ProShares Pet Care ETF	N/A	N/A	N/A	N/A	N/A	N/A
PETQ PetIQ	$1.10B	0.84	$2.68 per share	11.54	$7.58 per share	4.09
PFE Pfizer	$63.63B	2.14	$4.19 per share	5.70	$15.62 per share	1.53
ZTS Zoetis	$9.39B	7.00	$6.96 per share	21.30	$10.57 per share	14.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELAN Elanco Animal Health	$338M	$0.86	21.53	20.81	3.49	9.68%	7.04%	3.45%	11/6/2025 (Estimated)
IDXX IDEXX Laboratories	$887.87M	$12.01	53.38	47.21	4.18	24.41%	64.42%	29.89%	10/30/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	49.34	24.26	1.05	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
PAWZ ProShares Pet Care ETF	N/A	N/A	23.65	∞	N/A	N/A	N/A	N/A	N/A
PETQ PetIQ	$2.13M	$0.39	79.44	24.59	N/A	1.20%	18.75%	5.15%	N/A
PFE Pfizer	$8.03B	$1.88	12.72	7.89	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.81	25.53	21.97	2.42	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ELAN Elanco Animal Health	$0.1989	$0.26	+$0.0611	$0.02	$1.19 billion	$1.24 billion
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
8/4/2025	Q2 2025	IDXX IDEXX Laboratories	$3.28	$3.63	+$0.35	$3.63	$1.06 billion	$1.11 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.79%	N/A	39.22%	11 Years
PAWZ ProShares Pet Care ETF	$0.42	0.74%	N/A	N/A	N/A
PETQ PetIQ	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.19%	N/A	91.49%	16 Years
ZTS Zoetis	$2.00	1.35%	N/A	34.42%	14 Years

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELAN Elanco Animal Health	0.61	2.60	1.40
IDXX IDEXX Laboratories	0.31	1.11	0.79
LLY Eli Lilly and Company	1.86	1.28	1.00
PAWZ ProShares Pet Care ETF	N/A	N/A	N/A
PETQ PetIQ	1.68	2.58	1.68
PFE Pfizer	0.65	1.16	0.85
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELAN Elanco Animal Health	97.48%
IDXX IDEXX Laboratories	87.84%
LLY Eli Lilly and Company	82.53%
PAWZ ProShares Pet Care ETF	N/A
PETQ PetIQ	94.99%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ELAN Elanco Animal Health	0.89%
IDXX IDEXX Laboratories	0.98%
LLY Eli Lilly and Company	0.13%
PAWZ ProShares Pet Care ETF	N/A
PETQ PetIQ	9.62%
PFE Pfizer	0.06%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELAN Elanco Animal Health	9,000	496.81 million	492.39 million	Optionable
IDXX IDEXX Laboratories	11,000	80.00 million	79.22 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
PAWZ ProShares Pet Care ETF	N/A	1.08 million	N/A	Not Optionable
PETQ PetIQ	1,933	29.89 million	27.01 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
ZTS Zoetis	13,800	443.18 million	442.39 million	Optionable

ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Headlines

Recent News About These Companies

Zoetis (ZTS) Gains Positive Opinion For Portela Therapy In EU For Cat OA Pain Relief

September 13 at 3:42 PM | finance.yahoo.com

Advisors Capital Management LLC Raises Holdings in Zoetis Inc. $ZTS

September 13 at 6:33 AM | marketbeat.com

Geneos Wealth Management Inc. Has $3.59 Million Position in Zoetis Inc. $ZTS

September 13 at 5:35 AM | marketbeat.com

SCS Capital Management LLC Makes New Investment in Zoetis Inc. $ZTS

September 13 at 4:45 AM | marketbeat.com

Great Lakes Advisors LLC Has $2.69 Million Stake in Zoetis Inc. $ZTS

September 13 at 4:19 AM | marketbeat.com

Caxton Associates LLP Makes New Investment in Zoetis Inc. $ZTS

September 13 at 4:08 AM | marketbeat.com

Jacobs Levy Equity Management Inc. Purchases Shares of 11,638 Zoetis Inc. $ZTS

September 13 at 3:41 AM | marketbeat.com

Zoetis announces positive opinion from CVMP for Portela

September 12 at 8:49 PM | msn.com

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

September 12 at 12:40 PM | zacks.com

Zoetis Inc. (ZTS) Secures a New Five-Year $1.25 Billion Senior Unsecured Revolving Credit Facility

September 12 at 12:11 PM | insidermonkey.com

Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

September 12 at 12:09 PM | businesswire.com

Zoetis Inc. (ZTS) Secures a New Five-Year $1.25 Billion Senior Unsecured Revolving Credit Facility

September 12 at 11:31 AM | finance.yahoo.com

Bayforest Capital Ltd Increases Stake in Zoetis Inc. $ZTS

September 12 at 7:04 AM | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Stake in Zoetis Inc. $ZTS

September 12 at 6:42 AM | marketbeat.com

Zurich Insurance Group Ltd FI Cuts Stake in Zoetis Inc. $ZTS

September 12 at 6:40 AM | marketbeat.com

MBB Public Markets I LLC Purchases Shares of 1,900 Zoetis Inc. $ZTS

September 12 at 6:11 AM | marketbeat.com

Argus Reaffirms Buy Rating for Zoetis (NYSE:ZTS)

September 11 at 9:41 AM | marketbeat.com

Peloton Wealth Strategists Acquires 2,000 Shares of Zoetis Inc. $ZTS

September 11 at 5:54 AM | marketbeat.com

Zoetis Inc. $ZTS Holdings Raised by Ascent Group LLC

September 11 at 5:37 AM | marketbeat.com

Ashton Thomas Private Wealth LLC Sells 5,682 Shares of Zoetis Inc. $ZTS

September 11 at 4:44 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Jones Financial Companies Lllp

September 11 at 4:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Company Descriptions

Elanco Animal Health NYSE:ELAN

$18.52 -0.26 (-1.40%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$18.69 +0.17 (+0.94%)

As of 09/12/2025 07:55 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

IDEXX Laboratories NASDAQ:IDXX

$641.14 -4.02 (-0.62%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$644.06 +2.92 (+0.46%)

As of 09/12/2025 04:20 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Eli Lilly and Company NYSE:LLY

$754.90 -1.38 (-0.18%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$752.50 -2.40 (-0.32%)

As of 09/12/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

ProShares Pet Care ETF BATS:PAWZ

$56.44 +2.90 (+5.41%)

Closing price 09/12/2025 03:28 PM Eastern

Extended Trading

$56.44 0.00 (0.00%)

As of 09/12/2025 04:04 PM Eastern

The ProShares Pet Care ETF (PAWZ) is an exchange-traded fund that is based on the FactSet Pet Care index. The fund tracks a tier-weighted index of global equities related to pet ownership. PAWZ was launched on Nov 5, 2018 and is managed by ProShares.

PetIQ NASDAQ:PETQ

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Pfizer NYSE:PFE

$23.91 -0.95 (-3.82%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$23.96 +0.04 (+0.19%)

As of 09/12/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$148.33 -2.28 (-1.51%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$147.88 -0.46 (-0.31%)

As of 09/12/2025 07:51 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Earnings

Compare Dividends

Latest ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZTS, ELAN, PAWZ, PFE, LLY, PETQ, and IDXX Company Descriptions

Elanco Animal Health NYSE:ELAN

IDEXX Laboratories NASDAQ:IDXX

Eli Lilly and Company NYSE:LLY

ProShares Pet Care ETF BATS:PAWZ

PetIQ NASDAQ:PETQ

Pfizer NYSE:PFE

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools